source
- Menarini's Stemline signs $1.1 billion deal to license Georgiamune's preclinical cancer immunotherapyGeorgiamune, a Maryland‑based immunology biotech, has granted Stemline Therapeutics, part of Italy's Menarini Group, exclusive worldwide rights to develop and commercialize its preclinical cancer c…
- US Treasury proposes COINS Act rules that restrict biotech investment in China but leave big pharma licensing deals untouchedThe U.S. Treasury Department released draft regulations that add biotechnology to the Comprehensive Outbound Investment National Security (COINS) Act, labeling pharmaceutical compounds as prohibite…